Gua Lou Gui Zhi decoction attenuates post‑stroke spasticity via the modulation of GABAB receptors

Zhu,Xiaoqin; Hu,Haixia; Li,Zuanfang; Lin,Ruhui; Mao,Jingjie; Chen,Lidian

doi:10.3892/mmr.2015.4207

Gua Lou Gui Zhi decoction attenuates post‑stroke spasticity via the modulation of GABAB receptors

Authors:
- Xiaoqin Zhu
- Haixia Hu
- Zuanfang Li
- Ruhui Lin
- Jingjie Mao
- Lidian Chen
View Affiliations

Affiliations: Academy of Integrative Medicine Biomedical Research Center, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China, Fujian Key Laboratory of Exercise Rehabilitation, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China
Published online on: August 11, 2015 https://doi.org/10.3892/mmr.2015.4207
Pages: 5957-5962

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the mechanisms underlying the neuroprotective and antispastic effects of Gua Lou Gui Zhi decoction (GLGZD) in a rat model of middle cerebral artery occlusion (MCAO). The MCAO rats were treated with GLGZD (14.3 g/kg body weight) once a day for a period of seven days. Neurological deficit scores and screen tests were analyzed every other day. Following treatment with GLGZD for 7 days, the ischemic infarct volume of the rat brains was measured using 2,3,5‑triphenyl tetrazolium chloride staining. Reverse transcription‑polymerase chain reaction was performed in order to determine the mRNA expression levels of γ‑amino butyric acid B (γ‑GABAB) receptor (R) in the cortical infarct region. Furthermore, the protein expression levels of GABAB R were detected in the cortical infarct region by western blot analysis. Following 7 days, treatment with GLGZD significantly ameliorated the neurological defects and cerebral infarction in the MCAO rats. In addition, treatment with GLGZD ameliorated motor performance in the MCAO rats, as determined by screen tests. Furthermore, GLGZD was able to upregulate the mRNA and protein expression levels of GABAB1 R and GABAB2 R in the ischemic cerebral cortex. The results of the present study suggested that GLGZD may exert neuroprotective and antispastic effects in a cerebral ischemia model, through upregulating the expression of GABAB R.

View Figures

View References

1	Donnan GA, Fisher M, Macleod M and Davis SM: Stroke. Lancet. 371:1612–1623. 2008. View Article : Google Scholar : PubMed/NCBI
2	Mayer NH and Esquenazi A: Muscle overactivity and movement dysfunction in the upper motoneuron syndrome. Phys Med Rehabil Clin N Am. 14:855–883. 2003. View Article : Google Scholar : PubMed/NCBI
3	Sommerfeld DK, Eek EU, Svensson AK, Holmqvist LW and von Arbin MH: Spasticity after stroke: Its occurrence and association with motor impairments and activity limitations. Stroke. 35:134–139. 2004. View Article : Google Scholar
4	Lundström E, Terént A and Borg J: Prevalence of disabling spasticity 1 year after first-ever stroke. Eur J Neurol. 15:533–539. 2008. View Article : Google Scholar : PubMed/NCBI
5	Duncan PW, Zorowitz R, Bates B, Choi JY, Glasberg JJ, Graham GD, Katz RC, Lamberty K and Reker D: Management of Adult Stroke Rehabilitation Care: A clinical practice guideline. Stroke. 36:e100–e143. 2005. View Article : Google Scholar : PubMed/NCBI
6	Brown P: Pathophysiology of spasticity. J Neurol Neurosurg Psychiatry. 57:773–777. 1994. View Article : Google Scholar : PubMed/NCBI
7	Doan QV, Brashear A, Gillard PJ, Varon SF, Vandenburgh AM, Turkel CC and Elovic EP: Relationship between disability and health-related quality of life and caregiver burden in patients with upper limb poststroke spasticity. PM R. 4:4–10. 2012. View Article : Google Scholar
8	Liu CM, Li RQ, Song XL and Feng XD: Effect of catgut implantation at acupoints on GABAB and mGluR1 expressions in brain stem of rats with spasticity after stroke. J Tradit Chin Med. 34:566–571. 2014. View Article : Google Scholar : PubMed/NCBI
9	Ellenberger C, Mevissen M, Doherr M, Scholtysik G and Jaggy A: Inhibitory and excitatory neurotransmitters in the cerebrospinal fluid of epileptic dogs. Am J Vet Res. 65:1108–1113. 2004. View Article : Google Scholar : PubMed/NCBI
10	Ramanathan M, Babu CS, Justin A and Shanthakumari S: Elucidation of neuroprotective role of endogenous GABA and energy metabolites middle cerebral artery occluded model in rats. Indian J Exp Biol. 50:391–397. 2012.PubMed/NCBI
11	Yang JP, Zhang XQ, Wang XD and Wang KW: Inhibitory and excitatory amino acids in cerebral spinal fluid in children with cerebral palsy. Zhong Hua Xiao Er Wai Ke Za Zhi. 19:282–284. 1998.In Chinese.
12	Galvez T, Parmentier ML, Joly C, Malitschek B, Kaupmann K, Kuhn R, Bittiger H, Froestl W, Bettler B and Pin JP: Mutagenesis and modeling of the GABAB receptor extracellular domain support a venus flytrap mechanism for ligand binding. J Biol Chem. 274:13362–13369. 1999. View Article : Google Scholar : PubMed/NCBI
13	Benke D: GABAB receptor trafficking and interacting proteins: targets for the development of highly specific therapeutic strategies to treat neurological disorders? Biochem Pharmacol. 86:1525–1530. 2013. View Article : Google Scholar : PubMed/NCBI
14	Goldstein EM: Spasticity management: An overview. J Child Neurol. 16:16–23. 2001. View Article : Google Scholar : PubMed/NCBI
15	Lapeyre E, Kuks JB and Meijler WJ: Spasticity: Revisiting the role and the individual value of several pharmacological treatments. NeuroRehabilitation. 27:193–200. 2010.PubMed/NCBI
16	Simon O and Yelnik AP: Managing spasticity with drugs. Eur J Phys Rehabil Med. 46:401–410. 2010.PubMed/NCBI
17	Sun X: Research on formula treating paralysis and spasticity from 'treatise on febrile and miscellaneous diseases'. Zhongguo Zhong Yi Ji Chu Yi Xue Za Zhi. 8:644–645. 2010.In Chinese.
18	Yelnik AP, Simon O, Bensmail D, Chaleat-Valayer E, Decq P, Dehail P, Quentin V, Marque P, Parratte B, Pellas F, et al Agence française de sécurité sanitaire des produits de santé: Drug treatments for spasticity. Ann Phys Rehabil Med. 52:746–756. 2009. View Article : Google Scholar : PubMed/NCBI
19	Satkunam LE: Rehabilitation medicine: 3. Management of adult spasticity. CMAJ. 169:1173–119. 2003.PubMed/NCBI
20	Zhang L and Ai H: Effects of Gua Lou Gui Zhi decotion on c-fos and c-jun in epileptic rats. Chuan Hua Xi Zhong Yi Yao Yan Jiu Suo. 23:21–22. 2005.In Chinese.
21	Yang CM, Chen LD and Tao J: New usage of a classical formula-Gua Lou Gui Zhi decotion. Liao ning Zhong Yi Za Zhi. 8:166–167. 2012.In Chinese.
22	Chen YL, Chen LD and Tao J: Clinical research on treating limbs spam from cerebral apoplexy with Gualou Guizhi decoction. Clin J Chin Med. 5:7–9. 2013.In Chinese.
23	Huang J, Tao J, Xue XH, Yang S, Han P, Lin Z, Xu W, Lin J, Peng J and Chen L: Gua Lou Gui Zhi decoction exerts neuroprotective effects on post-stroke spasticity via the modulation of glutamate levels and AMPA receptor expression. Int J Mol Med. 31:841–848. 2013.PubMed/NCBI
24	Chen X, Li H, Huang M, Huang M, Xu W, Chu K, Chen L and Zhang Y: Effect of Gua Lou Gui Zhi decoction on focal cerebral ischemia-reperfusion injury through regulating the expression of excitatory amino acids and their receptors. Mol Med Rep. 10:248–254. 2014.PubMed/NCBI
25	Chalifoux JR and Carter AG: GABAB receptor modulation of synaptic function. Curr Opin Neurobiol. 21:339–344. 2011. View Article : Google Scholar : PubMed/NCBI
26	Oshiro M, Hefferan MP, Kakinohana O, Lukacova N, Sugahara K, Yaksh TL and Marsala M: Suppression of stretch reflex activity after spinal or systemic treatment with AMPA receptor antagonist NGX424 in rats with developed baclofen tolerance. Br J Pharmacol. 161:976–985. 2010. View Article : Google Scholar : PubMed/NCBI
27	Gómez-Soriano J, Goiriena E and Taylor J: Spasticity therapy reacts to astrocyte GluA1 receptor upregulation following spinal cord injury. Br J Pharmacol. 161:972–975. 2010. View Article : Google Scholar : PubMed/NCBI
28	Longa EZ, Weinstein PR, Carlson S and Cummins R: Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 20:84–91. 1989. View Article : Google Scholar : PubMed/NCBI
29	Guo J, Liu L, Ma C, Xu B, Duan X and Wang B: Effect of restraint stress on depression-like behaviors in rats after transient focal cerebral ischemic injury. Neural Regen Res. 2:390–394. 2007. View Article : Google Scholar
30	Mayer NH, Esquenazi A and Childers MK: Common patterns of clinical motor dysfunction. Muscle Nerve. (Suppl 6): S21–S35. 1997. View Article : Google Scholar : PubMed/NCBI
31	Doble A: The role of excitotoxicity in neurodenenerative disease: Implications for therapy. Pharmacol Ther. 81:163–221. 1999. View Article : Google Scholar : PubMed/NCBI
32	Bowery NG: GABAB receptor: a site of therapeutic benefit. Curr Opin Pharmacol. 6:37–43. 2006. View Article : Google Scholar
33	Bettler B, Kaupmann K, Mosbacher J and Gassmann M: Molecular structure and physiological functions of GABA(B) receptors. Physiol Rev. 84:835–867. 2004. View Article : Google Scholar : PubMed/NCBI
34	Gassmann M and Bettler B: Regulation of neuronal GABA(B) receptor functions by subunit composition. Nat Rev Neurosci. 13:380–394. 2012. View Article : Google Scholar : PubMed/NCBI
35	Chalifoux JR and Carter AG: GABAB receptor modulation of synaptic function. Curr Opin Neurobiol. 21:339–344. 2011. View Article : Google Scholar : PubMed/NCBI
36	Benarroch EE: GABAB receptors: Structure, functions, and clinical implications. Neurology. 78:578–584. 2012. View Article : Google Scholar : PubMed/NCBI